Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

BACKGROUND: Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-inte...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Moran, Antoinette, Bundy, Brian, Becker, Dorothy J, DiMeglio, Linda A, Gitelman, Stephen E, Goland, Robin, Greenbaum, Carla J, Herold, Kevan C, Marks, Jennifer B, Raskin, Philip, Sanda, Srinath, Schatz, Desmond, Wherrett, Diane K, Wilson, Darrell M, Krischer, Jeffrey P, Skyler, Jay S, Pickersgill, Linda, de Koning, Eelco, Ziegler, Anette-G, Böehm, Bernhard, Badenhoop, Klaus, Schloot, Nanette, Bak, Jens Friis, Pozzilli, Paolo, Mauricio, Didac, Donath, Marc Y, Castaño, Luis, Wägner, Ana, Lervang, Hans Henrik, Perrild, Hans, Poulsen, Thomas Mandrup
格式: Artigo
語言:Inglês
出版: 2013
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3827771/
https://ncbi.nlm.nih.gov/pubmed/23562090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(13)60023-9
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍